Vertex Ends Part of Hepatitis Drug Test

[Guest guest]

CDC 12-30-10

UNITED STATES: " Vertex Ends Part of Hepatitis Drug Test "

Boston Globe (12.22.10)

Vertex Pharmaceuticals is discontinuing a clinical study of its hepatitis C drug

telaprevir in combination with VX-222, another experimental therapy developed by

the company. Vertex said it will continue Phase II testing of telaprevir and

VX-222 in groups of patients who will receive these with one or two other drugs

given as a combination treatment. The Cambridge, Mass.-based company partnered

with & to develop telaprevir, which is Vertex's most advanced

experimental hepatitis C drug. There are no medicines available for hepatitis C

patients who do not respond to standard treatment. Hepatitis C affects roughly 4

million Americans and 200 million worldwide, according to the National

Institutes of Health.

[Guest guest]

CDC 12-30-10

UNITED STATES: " Vertex Ends Part of Hepatitis Drug Test "

Boston Globe (12.22.10)

Vertex Pharmaceuticals is discontinuing a clinical study of its hepatitis C drug

telaprevir in combination with VX-222, another experimental therapy developed by

the company. Vertex said it will continue Phase II testing of telaprevir and

VX-222 in groups of patients who will receive these with one or two other drugs

given as a combination treatment. The Cambridge, Mass.-based company partnered

with & to develop telaprevir, which is Vertex's most advanced

experimental hepatitis C drug. There are no medicines available for hepatitis C

patients who do not respond to standard treatment. Hepatitis C affects roughly 4

million Americans and 200 million worldwide, according to the National

Institutes of Health.